4-羟基-3-硝基苄醇 | 41833-13-0

• 物质功能分类: 有机原料 - 醇、酚、酚醇类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: 4-羟基-3-硝基苄醇
• 中文别名: 3-硝基-4羟基苄醇
• 英文名称: 4-hydroxymethyl-2-nitrophenol
• 英文别名: 4-hydroxy-3-nitrobenzyl alcohol；4-(hydroxymethyl)-2-nitrophenol
• CAS: 41833-13-0
• 化学式: C₇H₇NO₄
• 分子量: 169.137
• InChiKey: IMLGJYRKLCMJPI-UHFFFAOYSA-N

物化性质

• 熔点：
  94-98 °C
• 沸点：
  298.4°C (rough estimate)
• 密度：
  1.4523 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  86.3
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn,Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  2908999090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H319
• 储存条件：
  存放于阴凉干燥处即可。

SDS

Name:	4-Hydroxy-3-nitrobenzyl alcohol Material Safety Data Sheet
Synonym:	None Known
CAS:	41833-13-0

Section 1 - Chemical Product MSDS Name:4-Hydroxy-3-nitrobenzyl alcohol Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
41833-13-0	4-Hydroxy-3-nitrobenzyl alcohol	100	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 41833-13-0: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: light brown - bright yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H7NO4
Molecular Weight: 169.0533

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 41833-13-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Hydroxy-3-nitrobenzyl alcohol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 41833-13-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 41833-13-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 41833-13-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-羟基-3-硝基苄醇 在 manganese (II) nitrate tetrahydrate 、 copper(II) nitrate trihydrate 、 溶剂黄146 作用下， 以 三氟甲苯 为溶剂， 反应 2.0h， 以91%的产率得到4-羟基-3-硝基苯甲醛
  参考文献：
  名称：

  TEMPO包覆的Fe3O4超顺磁性纳米粒子的简单制备及其在酒精选择性氧化中的应用

  摘要：

  通过使用强金属氧化物螯合膦酸酯和叠氮化物/炔烃“咔嗒”化学反应，将有机氧化剂TEMPO（2,2,4,4-四甲基哌啶-1-氧基）固定在氧化铁（Fe 3 O 4）超顺磁性纳米粒子上。这种简单的制备方法可产生具有良好TEMPO负载的可回收TEMPO涂层纳米颗粒。它们具有出色的磁响应，并能在需氧酸性Mn II / Cu II下有效地催化多种伯醇和仲醇氧化成醛，酮和内酯。氧化Minisci条件或碱性NaOCl Anelli条件。纳米颗粒在Minisci条件下可以循环使用20次以上，在Anelli条件下可以循环使用八次，具有良好的基材转化率和优异的产品选择性。通过膦酸酯键固定化催化剂可使颗粒在最少的催化剂浸出的情况下承受酸性氧化环境。在固定膦酸酯之前而不是之后，将TEMPO单击膦酸酯，以确保单击的催化剂是颗粒表面上唯一的物质。这有助于定量催化剂负载。膦酸酯连接基的稳定性和这种催化剂固定方法的简便性使其

  DOI：

  10.1002/chem.200903527
• 作为产物：
  描述：

  对羟基苯甲醇 在 aluminium trinitrate 作用下， 以 乙腈 为溶剂， 以73%的产率得到4-羟基-3-硝基苄醇
  参考文献：
  名称：

  碘（III）通过非布朗斯台德酸性NO 2 +生成的苯酚亲电硝化

  摘要：

  使用碘基苯作为基于碘（III）和硝酸铝作为硝基基团来源的有机催化剂，开发了用于苯酚亲电硝化的第一个催化程序。该原子经济方案发生在温和的，非布朗斯台德酸性和开放式烧瓶反应条件下，具有宽泛的官能团耐受性，包括多个杂环。（SMD：MeCN）Mo8-HX /（LANLo8 + f，6-311 + G *）水平的密度泛函理论（DFT）计算表明反应通过阳离子途径进行，该途径有效地产生了NO 2 +离子，从而是中性条件下的硝化物种。

  DOI：

  10.1021/acs.orglett.8b04141

文献信息

• Heterocyclic ketones
  申请人：ICI Americas Inc.

  公开号：US05164371A1

  公开（公告）日：1992-11-17

  The invention provides a series of novel heterocyclic ketones of formula I ##STR1## and pharmaceutically acceptable base-addition salts thereof, in which the values of R.sup.4, L, A, X and Q have the meanings defined in the following specification. The compounds of formula I are inhibitors of human leukocytic elastase. The invention also provides pharmaceutical compositions containing a compound of formula I, or a pharmaceutically acceptable base-addition salt thereof, and processes and intermediates for the manufacture of compounds of formula I.

  这项发明提供了一系列新颖的杂环酮化合物，其化学式为I ##STR1## 及其药用可接受的盐，其中R.sup.4、L、A、X和Q的值如下文规定。化合物I的是人类白细胞弹性蛋白酶的抑制剂。该发明还提供了含有化合物I或其药用可接受的盐的药物组合物，以及化合物I的制备过程和中间体。
• Prodrugs of a JAK Inhibitor Compound for Treatment of Gastrointestinal Inflammatory Disease
  申请人：THERAVANCE BIOPHARMA R&D IP, LLC

  公开号：US20170145044A1

  公开（公告）日：2017-05-25

  The invention provides compounds which are prodrugs of a JAK inhibitor agent for the targeted delivery of the JAK inhibitor to the gastrointestinal tract of a mammal. The invention also provides pharmaceutical compositions comprising the compounds, methods of using the compounds to treat gastrointestinal inflammatory diseases, and processes and intermediates useful for preparing the compounds.

  本发明提供了一种前药化合物，它是针对哺乳动物胃肠道靶向输送JAK抑制剂的前药。本发明还提供了包含该化合物的药物组合物，使用该化合物治疗胃肠道炎症性疾病的方法，以及用于制备该化合物的过程和中间体。
• [EN] COMPOSITIONS AND METHODS RELATED TO ANTI-CD19 ANTIBODY DRUG CONJUGATES<br/>[FR] COMPOSITIONS ET MÉTHODES ASSOCIÉES À DES CONJUGUÉS ANTICORPS ANTI-CD19-MÉDICAMENTS
  申请人：LEGOCHEM BIOSCIENCES INC

  公开号：WO2017051249A1

  公开（公告）日：2017-03-30

  In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-CD 19 antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

  在某些方面，本发明涉及一种抗体药物偶联物，包括：一种抗CD19抗体；一个连接器；和一个活性剂。抗体药物偶联物可以包括一个自焚基团。连接器可以包括一个O-取代的肟，例如，肟的氧原子被一个与活性剂共价连接的基团所取代；肟的碳原子被一个与抗体共价连接的基团所取代。
• [EN] COMPOSITIONS AND METHODS RELATED TO ANTI-EGFR ANTIBODY DRUG CONJUGATES<br/>[FR] COMPOSITIONS ET MÉTHODES ASSOCIÉES À DES CONJUGUÉS ANTICORPS ANTI-EGFR-MÉDICAMENTS
  申请人：LEGOCHEM BIOSCIENCES INC

  公开号：WO2017051254A1

  公开（公告）日：2017-03-30

  In some aspects, the invention relates to an antibody-drug conjugate, comprising an anti-epidermal growth factor receptor ("EGFR") antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the drug; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.

  在某些方面，本发明涉及一种抗体-药物偶联物，包括针对表皮生长因子受体（“EGFR”）的抗体；连接体；以及活性剂。抗体-药物偶联物可以包含自焚基团。连接体可以包含O-取代的肟，例如，其中肟的氧原子被取代以与药物共价连接的基团；肟的碳原子被取代以与抗体共价连接的基团。
• IRON OXIDE SUPPORTED RHODIUM CATALYST FOR NITROARENE REDUCTION
  申请人：King Fahd University of Petroleum and Minerals

  公开号：US20200298212A1

  公开（公告）日：2020-09-24

  A supported catalyst having rhodium particles with an average diameter of less than 1 nm disposed on a support material containing magnetic iron oxide (e.g. Fe 3 O 4 ). A method of producing the supported catalyst and a process of reducing nitroarenes to corresponding aromatic amines employing the supported catalyst with a high product yield are also described. The supported catalyst may be recovered with ease using an external magnet and reused.

  一个支撑的催化剂，其上分布有平均直径小于1纳米的铑颗粒，载体材料含有磁性氧化铁（例如Fe3O4）。还描述了生产该支撑催化剂的方法以及使用该支撑催化剂将硝基芳烃还原为相应芳香胺的过程，该过程具有高产品收率。可以使用外部磁铁轻松回收支撑催化剂，并重复使用。

表征谱图